Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecovirimat versus placebo for symptomatic mpox
jRCT2031230473Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in mpox comparing Tecovirimat with Placebo (2 arms). Primary endpoint: Time to clinical resolution. Started Feb 2024; status: completed.
02
Drugs
tecovirimat
03
Conditions
mpox
Beyond the preview
Go deeper on jRCT2031230473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230473.